J
John G.F. Cleland
Researcher at National Institutes of Health
Publications - 1276
Citations - 125527
John G.F. Cleland is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Heart failure & Ejection fraction. The author has an hindex of 137, co-authored 1172 publications receiving 110227 citations. Previous affiliations of John G.F. Cleland include Northwestern University & Imperial College London.
Papers
More filters
Journal ArticleDOI
Natriuretic peptides for heart failure. Fashionable? Useful? Necessary?
John G.F. Cleland,Kevin Goode +1 more
Journal ArticleDOI
Co-expression of renin-angiotensin system component genes in human atrial tissue.
Kevin Morgan,John Wharton,Julie C. Webb,Bruce E. Keogh,Peter L. C. Smith,Kenneth M. Taylor,Celia M. Oakley,Julia M. Polak,John G.F. Cleland +8 more
TL;DR: The essential components of the rennin—angiotensin system are co-expressed at a low level in the right atrial appendage and are detectable in other regions of the human heart.
Journal ArticleDOI
Impact of mitral regurgitation in patients with worsening heart failure: Insights from BIOSTAT-CHF
Matteo Pagnesi,Marianna Adamo,Iziah E Sama,Stefan D. Anker,John G.F. Cleland,John G.F. Cleland,Kenneth Dickstein,Kenneth Dickstein,Gerasimos Filippatos,Chim C. Lang,Leong L. Ng,Leong L. Ng,Piotr Ponikowski,Alice Ravera,Nilesh J. Samani,Nilesh J. Samani,Faiez Zannad,Dirk J. van Veldhuisen,Adriaan A. Voors,Marco Metra +19 more
TL;DR: The role of mitral regurgitation in the BIOlogy Study to TAilored Treatment in chronic heart failure (BIOSTAT-CHF) was investigated in this paper.
ACC/AHA HEART FAILURE CLINICAL DATA STANDARDS ACC/AHA Key Data Elements and Definitions for Measuring the Clinical Management and Outcomes of Patients With Chronic Heart Failure A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Heart Failure Clinical Data Standards) Endorsed by the Heart Failure Society of America
Martha J. Radford,J. Malcolm O. Arnold,Susan J. Bennett,John G.F. Cleland,John D. Rutherford,Lynne W. Stevenson +5 more
Journal ArticleDOI
Progression from Hypertension to Heart Failure
TL;DR: Carvedilol, a non-selective beta-blocker which also has other ancillary properties including alpha-1-receptor blockade and antioxidant effects and a favourable metabolic profile, may be an appropriate choice for the prevention of HF in hypertensive patients.